The buyer's name comes with a city attached: Merck KGaA, Darmstadt, Germany.
$SLN +125.52%. This morning Silence Therapeutics announced it has entered into an agreement to be acquired. The buyer framed it as strengthening its rare disease pipeline with an siRNA asset. Less than two hours later, law firm Halper Sadeh announced it is investigating whether Silence shareholders are getting a fair price.
The second headline is the more useful one. Once a target signs an agreement, the stock stops trading the science and starts trading the deal: the offer, the timing, whether it closes. None of the terms are in our feed. Without the offer price, you can't tell whether you're paying for upside or for a thin spread to a number you haven't read.
The cross-stock history doesn't fix that. Across 3,383 prior sessions where stocks opened 30% or more above the prior close, 66% closed below their open. That bucket isn't filtered for buyouts. It puts acquisition targets and press-release pops in the same pile, and they behave for different reasons.
The agreement is signed. The deal isn't completed. The fair-price question is still open, and the figure that answers it isn't in this headline.